Cell Division Cycle 42 (Cdc42) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Cell Division Cycle 42 (Cdc42) | |
|---|---|
| Gene | CDC42 |
| UniProt ID | P60953 |
| PDB Structure IDs | 1E0A, 2NGR, 1AG5 |
| Molecular Weight | 21,200 Da |
| Subcellular Localization | Cytoplasm (membrane-associated when active); plasma membrane |
| Protein Family | Rho GTPase family (RhoA, Rac1, Cdc42) |
CDC42 is a small GTPase that regulates actin cytoskeleton dynamics, cell polarity, and membrane trafficking. It is essential for neuronal development and synaptic function.
Cell Division Cycle 42 (Cdc42) is a Rho GTPase family (RhoA, Rac1, Cdc42) member.
CDC42 cycles between active (GTP-bound) and inactive (GDP-bound) states. GTPase activity is enhanced by GTPase-activating proteins (GAPs), while nucleotide exchange factors (GEFs) promote GDP release and GTP binding. Effectors include WASP/WAVE complex (actin polymerization), PAK1 (p21-activated kinase), IQGAP (scaffold), and MRCK. In neurons, CDC42 regulates dendritic arborization, spine formation, axonal guidance, and neurotransmitter release.
CDC42 dysregulation contributes to synaptic loss in AD (Aβ reduces CDC42 signaling), dendritic degeneration in PD (LRRK2 mutations affect CDC42), and motor neuron dysfunction in ALS. Mutations in CDC42 or its regulators cause neurodevelopmental disorders including intellectual disability and autism.
CDC42 inhibitors include ML141 (CID2950003), Secramine (blocks GEF interaction). Activators include CNF1 (cytolethal distending toxin from bacteria). Gene therapy approaches aim to restore CDC42 signaling in specific neuronal populations.
ATF4 is widely expressed in the central nervous system, with high levels in the hippocampus, cortex, and hypothalamus. It is induced by cellular stress including oxidative stress, amino acid deprivation, and endoplasmic reticulum stress.
In Alzheimer's disease, ATF4 dysregulation contributes to synaptic plasticity impairment and memory deficits. In Parkinson's disease, ATF4 is involved in the cellular response to dopaminergic neuron stress. In ALS, ATF4 regulates the expression of genes involved in motor neuron survival.
Targeting ATF4 expression or activity represents a potential therapeutic approach for neurodegenerative diseases. Small molecule activators of ATF4 may provide neuroprotective effects.
ATF4 knockout mice show deficits in long-term memory and synaptic plasticity. Transgenic mice overexpressing ATF4 have been used to study its role in neurodegeneration.
Future research should focus on understanding the cell-type specific functions of ATF4 and developing ATF4-targeted therapeutics.
The study of Cell Division Cycle 42 (Cdc42) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] https://pubmed.ncbi.nlm.nih.gov/14657250/
[2] https://pubmed.ncbi.nlm.nih.gov/15660156/
[3] https://pubmed.ncbi.nlm.nih.gov/18669862/
[4] https://pubmed.ncbi.nlm.nih.gov/21471211/
[5] https://pubmed.ncbi.nlm.nih.gov/24711158/
[6] https://pubmed.ncbi.nlm.nih.gov/26431658/
[7] https://pubmed.ncbi.nlm.nih.gov/28992421/
[8] https://pubmed.ncbi.nlm.nih.gov/31222207/
ATF4 is widely expressed in the central nervous system, with high levels in the hippocampus, cortex, and hypothalamus. It is induced by cellular stress including oxidative stress, amino acid deprivation, and endoplasmic reticulum stress.
In Alzheimer's disease, ATF4 dysregulation contributes to synaptic plasticity impairment and memory deficits. In Parkinson's disease, ATF4 is involved in the cellular response to dopaminergic neuron stress. In ALS, ATF4 regulates the expression of genes involved in motor neuron survival.
Targeting ATF4 expression or activity represents a potential therapeutic approach for neurodegenerative diseases. Small molecule activators of ATF4 may provide neuroprotective effects.
ATF4 knockout mice show deficits in long-term memory and synaptic plasticity. Transgenic mice overexpressing ATF4 have been used to study its role in neurodegeneration.
Future research should focus on understanding the cell-type specific functions of ATF4 and developing ATF4-targeted therapeutics.